W.G. Shaheen & Associates DBA Whitney & Co Boosts Stake in Novo Nordisk A/S $NVO

W.G. Shaheen & Associates DBA Whitney & Co lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 10.1% in the 4th quarter, HoldingsChannel reports. The firm owned 262,783 shares of the company’s stock after acquiring an additional 24,037 shares during the period. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in Novo Nordisk A/S were worth $13,370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth $25,000. Strengthening Families & Communities LLC purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth $30,000. WealthCollab LLC increased its stake in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares in the last quarter. Finally, American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the 4th quarter worth $28,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective for the company. The Goldman Sachs Group restated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, Wolfe Research began coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Erste Group modestly raised FY2026 and FY2027 EPS estimates for NVO (small upward revision to consensus-driven forecasts), a mild vote of confidence from an analyst that supports near-term earnings outlook.
• Positive Sentiment: Novo will present new Wegovy and next?generation obesity data at the European Congress on Obesity, highlighting oral semaglutide and higher?dose Wegovy data that could support future label expansions and sales recovery. Novo Nordisk to present new data on Wegovy at ECO
• Positive Sentiment: Analyst commentary highlights Novo’s strategy—oral Ozempic launches and pediatric label expansions—as potential levers to revive near?term growth, which could mitigate pricing/competitive headwinds if uptake is strong. Can Oral Ozempic and Label Expansions Revive NVO’s Near?Term Growth?
• Neutral Sentiment: Valuation and share?price swing pieces note large multi?month moves and ask whether the current price reflects fundamentals—useful context for longer?term investors but not an immediate catalyst. Is Novo Nordisk Pricing Reflect Recent Share Price Swings?
• Negative Sentiment: Health Canada approved the first generic version of Ozempic (Dr. Reddy’s), marking the first G7 market to clear a competitor — a clear near?term threat to pricing and market share for semaglutide products. This regulatory precedent increases investor concern about accelerating generic competition across other markets. Health Canada approves first generic version of Novo’s Ozempic
• Negative Sentiment: Rival drugmakers are delivering step?change results: Eli Lilly’s retatrutide produced ~28.7% mean weight loss (surgical?level results), shifting competitive dynamics and raising the bar for market share in obesity treatments. That outcome raises medium/long?term pressure on Novo’s premium pricing and growth. Retatrutide Crosses the Surgical Threshold
• Negative Sentiment: Other pipeline competitors are advancing (Boehringer’s survodutide Phase 3 results flagged “Wegovy?like” weight loss) and large entrants like Amazon are moving into GLP?1 distribution, both of which augment pricing and market?share risk for Novo. Boehringer survodutide Phase 3 results

Novo Nordisk A/S Stock Down 2.2%

Shares of NYSE:NVO opened at $40.28 on Thursday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a market cap of $179.85 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 9.80 and a beta of 0.73. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a 50-day moving average price of $38.62 and a 200 day moving average price of $47.36.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.34 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 50.14%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.